Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
Objectives This study analyzed the safety of coronavirus disease 2019 (COVID-19) bivalent and monovalent booster vaccines, including the frequency of adverse events (AEs) such as myocarditis and pericarditis, in adolescents aged 12 to 17 years in the Republic of Korea. We aimed to share the safety p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korea Disease Control and Prevention Agency
2024-08-01
|
| Series: | Osong Public Health and Research Perspectives |
| Subjects: | |
| Online Access: | http://ophrp.org/upload/pdf/j-phrp-2024-0081.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850191915327160320 |
|---|---|
| author | Mijeong Ko Seontae Kim Seok-Kyoung Choi Seung Hwan Shin Yeon-Kyeng Lee Yunhyung Kwon |
| author_facet | Mijeong Ko Seontae Kim Seok-Kyoung Choi Seung Hwan Shin Yeon-Kyeng Lee Yunhyung Kwon |
| author_sort | Mijeong Ko |
| collection | DOAJ |
| description | Objectives This study analyzed the safety of coronavirus disease 2019 (COVID-19) bivalent and monovalent booster vaccines, including the frequency of adverse events (AEs) such as myocarditis and pericarditis, in adolescents aged 12 to 17 years in the Republic of Korea. We aimed to share the safety profile of the COVID-19 bivalent vaccine booster doses. Methods We analyzed the frequencies of AEs reported to the COVID-19 vaccination management system (CVMS) or self-reported through the text message survey (TMS). Diagnostic eligibility and causality with vaccines were compared using odds ratios (ORs) by vaccine type, and incidence rates per 100,000 person-days were calculated for confirmed cases of myocarditis and pericarditis following monovalent and bivalent booster doses. Results In the CVMS, the AE reporting rate (per 100,000 doses) was lower after the bivalent booster (66.5) than after the monovalent booster (264.6). Among the AEs reported for both monovalent and bivalent vaccines, 98.3% were non-serious and 1.7% were serious. According to the TMS, both local and systemic AEs were reported less frequently after the bivalent vaccination than after the monovalent vaccination in adolescents aged 12 to 17 years (p<0.001). The incidence rates per 100,000 person-days for confirmed myocarditis/pericarditis following monovalent and bivalent booster doses were 0.03 and 0.05, respectively; this difference was not statistically significant (OR, 1.797; 95% confidence interval, 0.210–15.386). Conclusion AEs in 12- to 17-year-olds following the bivalent booster were less frequent than those following the monovalent booster in the Republic of Korea, and no major safety issues were identified. However, the reporting rates for AEs were low. |
| format | Article |
| id | doaj-art-f98e1ed135ed4f25b14f1ff2d6802b27 |
| institution | OA Journals |
| issn | 2233-6052 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Korea Disease Control and Prevention Agency |
| record_format | Article |
| series | Osong Public Health and Research Perspectives |
| spelling | doaj-art-f98e1ed135ed4f25b14f1ff2d6802b272025-08-20T02:14:44ZengKorea Disease Control and Prevention AgencyOsong Public Health and Research Perspectives2233-60522024-08-0115436437410.24171/j.phrp.2024.0081782Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of KoreaMijeong Ko0Seontae Kim1Seok-Kyoung Choi2Seung Hwan Shin3Yeon-Kyeng Lee4Yunhyung Kwon5 Capital Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Seoul, Republic of Korea Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea Honam Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Gwangju, Republic of Korea Compensation and Support Center for COVID-19 Vaccine Injury, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaObjectives This study analyzed the safety of coronavirus disease 2019 (COVID-19) bivalent and monovalent booster vaccines, including the frequency of adverse events (AEs) such as myocarditis and pericarditis, in adolescents aged 12 to 17 years in the Republic of Korea. We aimed to share the safety profile of the COVID-19 bivalent vaccine booster doses. Methods We analyzed the frequencies of AEs reported to the COVID-19 vaccination management system (CVMS) or self-reported through the text message survey (TMS). Diagnostic eligibility and causality with vaccines were compared using odds ratios (ORs) by vaccine type, and incidence rates per 100,000 person-days were calculated for confirmed cases of myocarditis and pericarditis following monovalent and bivalent booster doses. Results In the CVMS, the AE reporting rate (per 100,000 doses) was lower after the bivalent booster (66.5) than after the monovalent booster (264.6). Among the AEs reported for both monovalent and bivalent vaccines, 98.3% were non-serious and 1.7% were serious. According to the TMS, both local and systemic AEs were reported less frequently after the bivalent vaccination than after the monovalent vaccination in adolescents aged 12 to 17 years (p<0.001). The incidence rates per 100,000 person-days for confirmed myocarditis/pericarditis following monovalent and bivalent booster doses were 0.03 and 0.05, respectively; this difference was not statistically significant (OR, 1.797; 95% confidence interval, 0.210–15.386). Conclusion AEs in 12- to 17-year-olds following the bivalent booster were less frequent than those following the monovalent booster in the Republic of Korea, and no major safety issues were identified. However, the reporting rates for AEs were low.http://ophrp.org/upload/pdf/j-phrp-2024-0081.pdfadolescentcovid-19mrna vaccinessafety |
| spellingShingle | Mijeong Ko Seontae Kim Seok-Kyoung Choi Seung Hwan Shin Yeon-Kyeng Lee Yunhyung Kwon Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea Osong Public Health and Research Perspectives adolescent covid-19 mrna vaccines safety |
| title | Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea |
| title_full | Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea |
| title_fullStr | Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea |
| title_full_unstemmed | Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea |
| title_short | Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea |
| title_sort | comparative safety of monovalent and bivalent mrna covid 19 booster vaccines in adolescents aged 12 to 17 years in the republic of korea |
| topic | adolescent covid-19 mrna vaccines safety |
| url | http://ophrp.org/upload/pdf/j-phrp-2024-0081.pdf |
| work_keys_str_mv | AT mijeongko comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea AT seontaekim comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea AT seokkyoungchoi comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea AT seunghwanshin comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea AT yeonkyenglee comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea AT yunhyungkwon comparativesafetyofmonovalentandbivalentmrnacovid19boostervaccinesinadolescentsaged12to17yearsintherepublicofkorea |